{"id":"placebo-peginterferon-alfa-2a","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"10-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Depression/psychiatric effects"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PEGinterferon alfa-2a is a pegylated form of interferon alfa-2a that binds to interferon-alpha receptors on immune cells and hepatocytes, triggering JAK-STAT signaling and upregulation of interferon-stimulated genes. This leads to enhanced natural killer cell activity, increased MHC expression, and direct antiviral effects. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to standard interferon alfa-2a.","oneSentence":"PEGinterferon alfa-2a is an immunomodulatory agent that enhances antiviral and anti-tumor immune responses by activating interferon signaling pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:17.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C (in combination with ribavirin)"},{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT06144697","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2024-01-29","conditions":"Healthy Participants","enrollment":267},{"nctId":"NCT04426968","phase":"PHASE2","title":"A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2021-06-18","conditions":"Hepatitis B, Chronic","enrollment":96},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT04798612","phase":"PHASE2","title":"Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2023-08-14","conditions":"Colon Cancer","enrollment":68},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01088659","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-16","conditions":"Hepatitis D, Chronic","enrollment":50},{"nctId":"NCT00100659","phase":"PHASE3","title":"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT00880763","phase":"PHASE2","title":"A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-20","conditions":"Hepatitis C","enrollment":90},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT03272009","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2017-09-21","conditions":"Hepatitis B, Chronic","enrollment":73},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT00932971","phase":"PHASE2","title":"HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis","status":"COMPLETED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2009-06","conditions":"Hepatitis D","enrollment":70},{"nctId":"NCT01439373","phase":"PHASE2","title":"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-07","conditions":"Hepatitis C, Chronic","enrollment":16},{"nctId":"NCT02401737","phase":"PHASE1","title":"Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients","status":"COMPLETED","sponsor":"Novira Therapeutics, Inc.","startDate":"2015-01-31","conditions":"Chronic Hepatitis B","enrollment":58},{"nctId":"NCT02112799","phase":"PHASE1","title":"Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients","status":"COMPLETED","sponsor":"Novira Therapeutics, Inc.","startDate":"2014-04-30","conditions":"Chronic Hepatitis B","enrollment":55},{"nctId":"NCT03125213","phase":"PHASE2","title":"A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects","status":"WITHDRAWN","sponsor":"Alios Biopharma Inc.","startDate":"2017-09-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01265511","phase":"PHASE2","title":"Study of SCY-635, Pegasys and Copegus in Hepatitis C","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2010-11","conditions":"Hepatitis C Infection","enrollment":10},{"nctId":"NCT01890200","phase":"PHASE3","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)","status":"WITHDRAWN","sponsor":"TCM Biotech International Corp.","startDate":"2015-06","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT00922207","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-07","conditions":"Hepatitis B, Chronic","enrollment":280},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT01179594","phase":"PHASE4","title":"A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2010-09-18","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01903954","phase":"PHASE2","title":"A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":283},{"nctId":"NCT01278134","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":170},{"nctId":"NCT00963885","phase":"PHASE2","title":"A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Hepatitis C, Chronic","enrollment":229},{"nctId":"NCT01185860","phase":"PHASE1","title":"A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Hepatitis C, Chronic","enrollment":59},{"nctId":"NCT01318694","phase":"PHASE3","title":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2011-03","conditions":"Hepatitis C","enrollment":1081},{"nctId":"NCT01183169","phase":"PHASE2","title":"Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2010-08","conditions":"Hepatitis C","enrollment":459},{"nctId":"NCT02716779","phase":"PHASE2","title":"Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT01485991","phase":"PHASE3","title":"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-02","conditions":"Hepatitis C","enrollment":771},{"nctId":"NCT02661477","phase":"PHASE2","title":"Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2016-05","conditions":"Rhinovirus Infection","enrollment":20},{"nctId":"NCT00077649","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":188},{"nctId":"NCT01323244","phase":"PHASE3","title":"A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-12","conditions":"Hepatitis C","enrollment":142},{"nctId":"NCT00854802","phase":"NA","title":"A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2009-01","conditions":"Chronic Hepatitis C","enrollment":290},{"nctId":"NCT01257204","phase":"PHASE2","title":"Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Hepatitis C Virus","enrollment":196},{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT01125189","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Hepatitis C Virus","enrollment":558},{"nctId":"NCT00874770","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-06","conditions":"Hepatitis C Infection","enrollment":74},{"nctId":"NCT00895882","phase":"PHASE2","title":"Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11","conditions":"Chronic Genotype 1 Hepatitis C Virus Infection","enrollment":""},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01309932","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01193361","phase":"PHASE2","title":"Ph IIA Study (SOC +/- NS5B)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10","conditions":"Hepatitis C Virus","enrollment":39},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01030432","phase":"PHASE2","title":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":"Hepatitis C Virus","enrollment":285},{"nctId":"NCT01017575","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":55},{"nctId":"NCT01725529","phase":"PHASE3","title":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":457},{"nctId":"NCT00947349","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-07","conditions":"Hepatitis C, Pharmacokinetics","enrollment":22},{"nctId":"NCT01011166","phase":"PHASE2","title":"Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Chronic Hepatitis C Infection","enrollment":81},{"nctId":"NCT01371604","phase":"PHASE2","title":"Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01197157","phase":"PHASE2, PHASE3","title":"Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2010-09","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00556504","phase":"PHASE2","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection","status":"COMPLETED","sponsor":"TCM Biotech International Corp.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":84},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00495391","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":64},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT01188772","phase":"PHASE2","title":"Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":147},{"nctId":"NCT01054729","phase":"PHASE2","title":"Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-01","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT00911963","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-04","conditions":"Hepatitis C","enrollment":49},{"nctId":"NCT01371578","phase":"PHASE2","title":"Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":163},{"nctId":"NCT00637923","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2008-03","conditions":"Chronic Hepatitis C","enrollment":112},{"nctId":"NCT01504581","phase":"PHASE1","title":"Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-03","conditions":"Healthy","enrollment":48},{"nctId":"NCT01271790","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Hepatitis C, Chronic","enrollment":245},{"nctId":"NCT01356160","phase":"PHASE2","title":"GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":351},{"nctId":"NCT01225380","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Chronic Hepatitis C Infection","enrollment":324},{"nctId":"NCT00987337","phase":"PHASE2","title":"Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Hepatitis, Hepatitis C","enrollment":288},{"nctId":"NCT00703118","phase":"PHASE3","title":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":663},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183},{"nctId":"NCT01797848","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00743795","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HCV Infection","enrollment":252},{"nctId":"NCT00516321","phase":"PHASE3","title":"Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT00983853","phase":"PHASE2","title":"Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-10","conditions":"Hepatitis C, HIV Infections","enrollment":62},{"nctId":"NCT00580801","phase":"PHASE2","title":"An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-01","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT00720434","phase":"PHASE2","title":"A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT00561015","phase":"PHASE2","title":"A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2007-12","conditions":"Hepatitis C, Chronic","enrollment":52},{"nctId":"NCT01054573","phase":"PHASE3","title":"VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2010-04","conditions":"Hepatitis C, Chronic","enrollment":90},{"nctId":"NCT00136318","phase":"PHASE3","title":"Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-01","conditions":"Depression","enrollment":208},{"nctId":"NCT00921180","phase":"PHASE4","title":"Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-02","conditions":"Hepatitis B, Chronic","enrollment":148},{"nctId":"NCT01273064","phase":"PHASE2","title":"Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders","status":"TERMINATED","sponsor":"Conatus Pharmaceuticals Inc.","startDate":"2011-01","conditions":"Hepatitis C","enrollment":114},{"nctId":"NCT00207311","phase":"PHASE4","title":"Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-08","conditions":"Fatty Liver, Hepatitis C","enrollment":30},{"nctId":"NCT01142700","phase":"PHASE2","title":"A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Chronic Hepatitis C Virus Genotype 1","enrollment":""},{"nctId":"NCT01178996","phase":"PHASE3","title":"Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":552},{"nctId":"NCT00114361","phase":"PHASE3","title":"48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2005-03","conditions":"Hepatitis B","enrollment":138},{"nctId":"NCT00040027","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-04","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500},{"nctId":"NCT00274495","phase":"PHASE4","title":"Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver","status":"TERMINATED","sponsor":"Beth Israel Medical Center","startDate":"2006-01","conditions":"Chronic Hepatitis C Infection, Fatty Liver","enrollment":30},{"nctId":"NCT00546442","phase":"PHASE4","title":"Treatment Insulin Resistence in HCV G-1 Patient","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2006-05","conditions":"Chronic Hepatitis C","enrollment":126},{"nctId":"NCT00221624","phase":"PHASE3","title":"Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2001-11","conditions":"HCV Infection, Hepatitis C, Chronic","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo + PEGinterferon alfa-2a","genericName":"placebo + PEGinterferon alfa-2a","companyName":"SciClone Pharmaceuticals","companyId":"sciclone-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEGinterferon alfa-2a is an immunomodulatory agent that enhances antiviral and anti-tumor immune responses by activating interferon signaling pathways. Used for Chronic hepatitis C (in combination with ribavirin), Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}